All Engines
Healthcare Economics Engine

Drug Pipeline Forecasting

Monitor FDA drug pipeline, model uptake probabilities for new therapies, and build financial reserves for gene therapies, CAR-T, and specialty approvals before they hit the market

Blindsided by New Therapies

Hemgenix gets FDA approval: $3.5M one-time gene therapy for hemophilia B. Your actuarial team didn't see it coming. No reserve built. One patient bankrupts your self-funded plan for the year. This happens quarterly now. The FDA pipeline is visible—you're just not watching it.

Gene Therapy Cost
$1M-$4M
one-time treatment
CAR-T Launch Price
$475K
per patient
New Approvals/Year
50-70
FDA novel therapies

✗ What Fails Without This Engine

  • •Reactive budgeting: therapy approved, patient identified, panic ensues
  • •No financial reserves for specialty pipeline—hit P&L with no warning
  • •Can't negotiate pre-approval: waiting until launch means you pay list price
  • •Population at risk unknown: don't know which members match trial inclusion criteria

Proactive Pipeline Intelligence

Our Drug Pipeline Forecasting Engine monitors FDA Phase 2/3 trials, models approval probabilities and launch timelines, identifies at-risk members in your population, and generates financial reserves with uptake forecasts. You see it coming 12-24 months before approval.

Pipeline Forecasting Algorithm
// Monitor FDA pipeline
pipeline_drugs = GET_fda_trials(
  phase: ["Phase 2", "Phase 3"],
  therapeutic_areas: [oncology, rare_disease, gene_therapy]
)

FOR each drug IN pipeline_drugs:
  // Approval probability
  approval_prob = HISTORICAL_rate(drug.phase, drug.therapeutic_area)
    Phase 2 → Phase 3: 30%
    Phase 3 → FDA approval: 58%
    Phase 3 oncology → approval: 48%
  
  // Launch timeline
  expected_approval_date = trial_completion + 
                          pdufa_review_period +
                          conditional_buffer
  
  // Population at risk
  eligible_members = MATCH_population(
    diagnosis_codes: drug.indication,
    severity_criteria: trial_inclusion,
    age_range: trial_demographics
  )
  
  // Uptake model
  IF approval_occurs:
    Year 1 uptake = MIN(eligible_count × 15%, capacity_constrained)
    Year 2 uptake = eligible_count × 35%
    Year 3 uptake = eligible_count × 55%
  
  // Financial reserve
  expected_cost = uptake_forecast × drug_price × approval_prob
  reserve_per_year = expected_cost / years_until_approval
  
  IF reserve_per_year > materiality_threshold:
    ALERT CFO and actuarial team
    BUILD reserve in trend assumption

Engineering Architecture

Core Components

  • FDA Pipeline Monitor: Track ClinicalTrials.gov + FDA PDUFA calendar
  • Approval Probability: Bayesian model using historical phase success rates
  • Member Matching: Identify eligible population from diagnosis codes + severity
  • Reserve Calculator: Build IBNR-style reserve for expected future cost

Forecasting Metrics

Pipeline Visibility
12-24 mo
pre-approval
Approval Accuracy
73%
Phase 3 predictions
Reserve Adequacy
92%
actual vs. forecast
Cost Avoidance
$500K-$2M
pre-negotiation

Real-World Applications

Hemophilia B Gene Therapy Reserve

  • •Hemgenix Phase 3 completion: January 2022
  • •Engine forecast approval probability: 65%, launch Q4 2022
  • •Identified 1 severe hemophilia B patient in 15K lives
  • •Expected cost: $3.5M × 65% = $2.28M
  • •Built $190K/month reserve over 12 months
  • •FDA approved November 2022 — reserve fully funded

CAR-T Pipeline Monitoring

  • •Monitored 8 CAR-T therapies in Phase 2/3 trials
  • •Matched 6 members with refractory lymphoma
  • •Approval forecast: 2 therapies expected within 18 months
  • •Built $950K reserve (2 × $475K)
  • •Negotiated preferred site-of-care before launch
  • •Actual cost: $390K per patient (18% below list)

See Tomorrow's Therapies Today

Monitor FDA pipeline. Identify at-risk members. Build financial reserves before approval. Negotiate pricing before launch. Never get blindsided again.

Request Engine Demo→